Literature DB >> 30853458

Morphological changes in the femoral and tibial bone tunnels after anatomic single-bundle anterior cruciate ligament reconstruction using a calcium phosphate-hybridized tendon graft in 2years of follow-up.

Hirotaka Mutsuzaki1, Tomonori Kinugasa2, Kotaro Ikeda2, Masataka Sakane3.   

Abstract

INTRODUCTION: A calcium phosphate (CaP)-hybridized tendon graft improves tendon-to-bone healing. The purpose of the study was to evaluate the progression of morphological changes in the femoral and tibial bone tunnels after anatomic single-bundle anterior cruciate ligament (ACL) reconstruction using the CaP-hybridized tendon graft versus an untreated tendon graft during 2 years of follow-up. HYPOTHESIS: We hypothesized that the CaP-hybridized tendon graft would prevent the progression of bone tunnel enlargement compared with the untreated tendon graft. PATIENTS AND METHODS: The CaP group comprised 19 patients, while the conventional group comprised 18. Computed tomography was performed at postoperative 1 week, 1 year, and 2 years. The bone tunnel enlargement and tunnel translation at the aperture of the femoral and tibial tunnels were analyzed.
RESULTS: In the CaP group, the femoral bone tunnel did not expand during 2 years of follow-up. In the conventional group, the femoral bone tunnel diameters at postoperative 1 year and 2 years were enlarged compared with postoperative 1 week, and the proximal and distal walls of the femoral bone tunnel shifted proximally and distally, respectively. The femoral bone tunnel in the CaP group was smaller than that in the conventional group at 1 year postoperatively. Although the tibial bone tunnels expanded for up to 1 year postoperatively in both groups, the expanded bone tunnel reduced during 2 years of follow-up only in the CaP group. DISCUSSION: In anatomic single-bundle ACL reconstruction, the femoral bone tunnel in the CaP group did not expand or progress with time compared with the conventional group, while the tibial bone tunnel in the CaP group expanded for up to 1 year postoperatively and then reduced for up to 2 years postoperatively. The CaP-hybridized tendon can prevent the progression of bone tunnel enlargement. LEVEL OF EVIDENCE: Level II, Low-powered prospective randomized trial.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anatomic single-bundle anterior cruciate ligament reconstruction; Bone tunnel enlargement; Calcium phosphate hybridization; Computed tomography; Morphological change

Mesh:

Substances:

Year:  2019        PMID: 30853458     DOI: 10.1016/j.otsr.2019.01.005

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  5 in total

1.  ACL graft with extra-cortical fixation rotates around the femoral tunnel aperture during knee flexion.

Authors:  Junjun Zhu; Brandon Marshall; Xin Tang; Monica A Linde; Freddie H Fu; Patrick Smolinski
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-09-09       Impact factor: 4.342

Review 2.  Bioaugmentation in the surgical treatment of anterior cruciate ligament injuries: A review of current concepts and emerging techniques.

Authors:  Austin MacFarland Looney; Joseph Daniel Leider; Andrew Ryan Horn; Blake Michael Bodendorfer
Journal:  SAGE Open Med       Date:  2020-05-12

3.  Cost-Effectiveness Analysis Based on Intelligent Electronic Medical Arthroscopy for the Treatment of Varus Knee Osteoarthritis.

Authors:  Chunfeng Liu; Zhen Wang; Jinlian Liu; Yaozeng Xu
Journal:  J Healthc Eng       Date:  2021-05-06       Impact factor: 2.682

Review 4.  Anterior Cruciate Ligament Reconstruction: Is Biological Augmentation Beneficial?

Authors:  Emerito Carlos Rodríguez-Merchán
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

5.  Effects of Platelet-Rich Plasma on Tendon-Bone Healing After Anterior Cruciate Ligament Reconstruction.

Authors:  Rong-Jin Chen; Hao-Zhong Zhu; Xin-Yi Gu; Xian-Xiang Xiang
Journal:  Orthop Surg       Date:  2021-12-06       Impact factor: 2.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.